iTeos Therapeutics, Inc. - Common Stock (NQ:ITOS)

10.15 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iTeos Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

The One-Minute Market Report - Sunday, Sept. 22 ↗

September 22, 2024

In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments...

Via Talk Markets

Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 17, 2024

Via Benzinga

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths ↗

September 16, 2024

Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.

Via Investor's Business Daily

Topics Death

Crude Oil Surges Over 1%; Instil Bio Shares Plunge ↗

September 16, 2024

Via Benzinga

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 16, 2024

Via Benzinga

Recap: ITeos Therapeutics Q4 Earnings ↗

March 06, 2024

Via Benzinga

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket ↗

September 16, 2024

Via Benzinga

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

September 14, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos to Participate in Upcoming Investor Conferences

August 28, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

August 20, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q2 2024 ↗

August 08, 2024

ITOS stock results show that ITeos Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates

August 08, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

August 05, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

July 08, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

June 17, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 28, 2024

Via Benzinga

ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024 ↗

May 10, 2024

ITOS stock results show that ITeos Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 10, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 10, 2024

Via Benzinga

Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday ↗

May 10, 2024

Via Benzinga

Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings ↗

May 10, 2024

Via Benzinga

Topics Stocks

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

May 10, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Therapeutics Announces $120 Million Registered Direct Offering

May 10, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

April 07, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023 ↗

March 06, 2024

ITOS stock results show that ITeos Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

March 06, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

March 06, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

March 05, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos to Participate in Upcoming Investor Conferences

March 01, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

January 08, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.